Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells

Journal of Neuro-Oncology
2005
Sean D. McAllister, Calvin Chan, Ryan J. Taft, Tri Luu, Mary E. Abood, Dan H. Moore, Ken Aldape, & Garret Yount

Normal tissue toxicity limits the efficacy of current treatment modalities for glioblastoma multiforme (GBM). We evaluated the influence of cannabinoids on cell proliferation, death, and morphology of human GBM cell lines and in primary human glial cultures, the normal cells from which GBM tumors arise. The influence of a plant derived cannabinoid agonist, D9 -tetrahydrocannabinol (D9 -THC), and a potent synthetic cannabinoid agonist, WIN 55,212- 2, were compared using time lapse microscopy. We discovered that D9 -THC decreases cell proliferation and increases cell death of human GBM cells more rapidly than WIN 55,212-2. D9 -THC was also more potent at inhibiting the proliferation of GBM cells compared to WIN 55,212-2. The effects of D9 -THC and WIN 55,212-2 on the GBM cells were partially the result of cannabinoid receptor activation. The same concentration of D9 -THC that significantly inhibits proliferation and increases death of human GBM cells has no significant impact on human primary glial cultures. Evidence of selective efficacy with WIN 55,212-2 was also observed but the selectivity was less profound, and the synthetic agonist produced a greater disruption of normal cell morphology compared to D9 -THC.

This library aims to empower you with knowledge but it does not replace the personalized advice and guidance a healthcare professional can provide. Before implementing any changes to your health regimen based on the contents of this library, we strongly advise you to consult with a qualified healthcare professional. Your doctor’s expertise is essential for interpreting how these insights may apply to your unique health circumstances.